By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chronix Biomedical said today that it has reeled in $1.8 million in Series E financing from existing and new investors that it is using to develop its serum-based disease tests.

The company's testing technology uses disease-specific biomarkers based on DNA fragments from damaged and dying cells that circulate in the bloodstream and are applicable to a range of cancers and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.